Reuters exclusively reports South Korea offers to produce mRNA vaccines

Reuters reported exclusively that South Korea is in talks with mRNA vaccine makers, including Pfizer and Moderna, to produce COVID-19 shots in the country and is ready to offer the capacity to make up to 1 billion doses immediately. The plan, if agreed, would help ease tight global supply of COVID-19 vaccines, particularly in Asia, and put South Korea a step closer to its ambition to become a major vaccine manufacturing center. According to a Reuters source, local vaccine makers, which have the capacity to produce mRNA vaccines immediately, include Hanmi Pharmaceuticals Co Ltd and Quratis Co Ltd.

Market Impact

Shares in Hanmi rose nearly 7% after the Reuters report, and its top shareholder Hanmi Science jumped 10.3%.

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Asia
Countries: South Korea
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Sign up for email updates